Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
86 hedge funds and large institutions have $99.9M invested in Cascadian Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 17 reducing their positions, and 13 closing their positions.
130% more call options, than puts
Call options by funds: $463K | Put options by funds: $201K
106% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 17
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 86 → 86 (0)
1% less capital invested
Capital invested by funds: $101M → $99.9M (-$684K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.05M |
| 2 |
BC
Broadfin Capital
New York
|
+$904K |
| 3 |
JP Morgan Chase
New York
|
+$696K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$575K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.5M |
| 2 |
DM
Deerfield Management
New York
|
-$3.35M |
| 3 |
QF
QVT Financial
New York
|
-$3.01M |
| 4 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
-$1.71M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.34M |
CASC Hedge Fund Activity: Q4 2014 in Review
86 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q4 2014, worth a combined $99.9M — down 0.68% from $101M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CASC positions and 13 closed out — a net gain of 1 holder — while 35 added to existing stakes and 17 trimmed.
The largest buyer was BVF Inc, adding an estimated $7.05M. The largest seller was Great Point Partners, exiting entirely with an estimated $7.5M sold.
- 86 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $99.9M of Cascadian Therapeutics, Inc. stock for Q4 2014, down 0.68% quarter-over-quarter.
- 14 funds opened new Cascadian Therapeutics, Inc. positions in Q4 2014 and 13 closed out, a net change of +1 holder.
- The largest Cascadian Therapeutics, Inc. buyer in Q4 2014 was BVF Inc, an estimated $7.05M added.
- The largest Cascadian Therapeutics, Inc. seller in Q4 2014 was Great Point Partners, an estimated $7.5M sold.
Based on aggregated 13F filings for Q4 2014.